John F. Greden

Pine Rest Christian Mental Health Services — United States

Medicine · Health Sciences

59h-index12.4kcitations288works6.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Treatment of Major Depression(78), Tryptophan and brain disorders(43), Stress Responses and Cortisol(34), Bipolar Disorder and Treatment(33), Schizophrenia research and treatment(32)

Publications287 total

Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study
Psychopharmacology Bulletin·2025· 4 citedOpen Access
Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer
Psychopharmacology Bulletin·2025· 8 citedOpen Access
Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial
Journal of Affective Disorders·2025· 2 citedOpen Access
High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant Depression
Biological Psychiatry Global Open Science·2025Open Access
Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial
Psychiatry Research·2024· 16 cited
Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression
Journal of Affective Disorders·2023· 9 cited
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression
Journal of Affective Disorders·2022· 10 cited
Reconstructing schizophrenia: Lessons from major mood disorders
Schizophrenia Research·2022· 2 cited
Patients’ recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression
Neuroscience Applied·2022· 1 citedOpen Access
Contributors
Elsevier eBooks·2022Open Access
Clinical outcomes in the biomarkers of ketamine (bio-k) study of open-label iv ketamine for non-psychotic depression or bipolar disorder
Neuroscience Applied·2022Open Access
Tools to aid precision treatments to prevent or manage treatment-resistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence
Elsevier eBooks·2022Open Access
Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder
Psychiatry Research·2021· 10 citedOpen Access
Depression on College Campuses Conference: Addressing an Evolving Crisis
Academic Psychiatry·2021· 1 citedOpen Access
PAULA J. CLAYTON, MD
Depression and Anxiety·2021
Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial
CNS Spectrums·2021· 3 citedOpen Access
Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression
FOCUS The Journal of Lifelong Learning in Psychiatry·2021· 1 citedOpen Access
Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression
Psychiatry Research·2020· 16 citedOpen Access
Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression
American Journal of Geriatric Psychiatry·2020· 28 citedOpen Access
Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder
Psychiatry Research·2020· 31 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Bernard J. Carroll(9), Michael Feinberg(8), Roger F. Haskett(6), Rajiv Tandon(4), Janet Tarika(4), Mohammad Ghaziuddin(3), Leon Grunhaus(3), Ziad Kronfol(3), Martin J. Lubetsky(3), A. Ariav Albala(3), Steven C. Dilsaver(3), Cheryl A. King(2), Neera Ghaziuddin(2), Sagar V. Parikh(2), Joseph Silva(2), M. Hariharan(2), T VanNoord(2), J.R. DeQuardo(2), Norman McI. James(2), Meir Steiner(2)